1. Introduction

Biological Collateral in Lending Law is a developing legal concept concerning the use of biological materials, biological resources, or rights associated with biological products as security for loans and other financial obligations.

The expression does not ordinarily refer to a separately recognized category of collateral under Indian law. Rather, it describes a range of legal questions arising when biological materials or biotechnology-related assets are offered, directly or indirectly, as security for lending.

The subject becomes particularly important as biotechnology, pharmaceutical research, agricultural genetics, tissue banking, and biomanufacturing create assets whose financial value may depend on biological characteristics, intellectual property rights, regulatory approvals, and future commercial applications.

For example, consider a biotechnology company that seeks a loan to develop a genetically engineered crop. The company might offer its patents, laboratory equipment, contractual rights, or inventory as collateral. However, offering physical biological material—such as human tissue, reproductive material, or genetic samples—raises additional questions about ownership, consent, legality, public policy, and the lender's ability to enforce its security.

The central legal question is:

To what extent may a lender accept biological materials or biotechnology-related rights as security for a debt, and what happens if the borrower defaults?

The answer depends on the nature of the biological asset, the rights held by the borrower, the applicable legislation, and the jurisdiction in which the lending transaction occurs.

This explanation focuses primarily on Indian law, with selected comparative cases from other jurisdictions.

2. Meaning and Scope of Biological Collateral

Biological collateral can be divided into several categories.

A. Biological materials

These include physical biological substances, such as:

• Human tissues and cells.
• Blood and biological specimens.
• Sperm, ova, and embryos.
• Plant seeds and germplasm.
• Animal genetic materials.
• Microbial cultures and biological samples.

Whether a particular material can lawfully be owned, transferred, pledged, or sold depends on the applicable law. The existence of scientific or commercial value does not automatically make a biological specimen freely transferable property.

For instance, Indian law specifically regulates transactions involving human organs and tissues, including prohibitions on certain commercial dealings.

B. Biotechnology intellectual property

A biotechnology enterprise may own or hold rights in:

• Patents covering eligible inventions.
• Plant breeders' rights.
• Copyright in qualifying scientific software and documentation.
• Trade secrets and confidential manufacturing processes.
• Contractual rights relating to licensed biological technologies.

These rights may have commercial value independent of the physical biological material itself.

A lender might therefore take security over eligible intellectual property or contractual rights without acquiring ownership of the underlying human tissue, genetic material, or biological specimen.

C. Biological products and commercial inventory

Potential assets include lawfully manufactured pharmaceutical products, agricultural biotechnology products, and other regulated biological goods.

Their suitability as collateral depends on matters such as:

1. Whether the borrower lawfully owns the goods.
2. Whether the goods may be transferred or sold.
3. Whether storage conditions preserve their value.
4. Whether regulatory restrictions limit their use.
5. Whether a lender could legally sell them following default.

Important distinction: A biological asset's scientific value, market value, and legal suitability as collateral are three different things. A specimen may be scientifically valuable but legally ineligible for commercial sale or enforcement.

3. Legal Framework Governing Biological Collateral in India

India does not have a single statute specifically titled the Biological Collateral in Lending Act. The subject must instead be analysed through existing laws governing secured transactions, biological materials, intellectual property, contracts, and regulated industries.

A. Indian Contract Act, 1872

The Indian Contract Act is central to the law of pledges.

Section 172: Definition of pledge

Section 172 defines a pledge as the bailment of goods as security for the payment of a debt or the performance of a promise. The borrower providing the security is the pawnor, and the lender receiving it is the pawnee. IndiaCode by eCourtsIndia

Applied to biological collateral, this raises several questions:

• Does the material legally qualify as goods capable of being pledged?
• Does the borrower have the legal right to provide it as security?
• Is possession capable of being transferred lawfully?
• Can the material be retained or sold without violating another law?

The section does not automatically establish that human tissue, embryos, or genetic material can be pledged. Their legal status must be assessed separately.

Section 173: Right of retainer

Section 173 generally permits a pawnee to retain pledged goods until the relevant debt or promise is satisfied.

However, a lender cannot assume that this right permits the retention of every biological specimen. Regulatory requirements, donor rights, contractual restrictions, and public-policy considerations may limit what can lawfully be retained.

Section 176: Rights upon default

Section 176 provides that when a pawnor defaults, the pawnee may sue for the debt while retaining the pledged goods or sell the pledged goods after giving reasonable notice. If the sale proceeds are insufficient, the borrower remains liable for the balance. IndiaCode by eCourtsIndia

This provision becomes particularly complicated where biological material is involved.

Suppose a biotechnology company defaults on a loan secured against a biological research inventory. Before selling the inventory, the lender must determine whether the materials are legally transferable, whether regulatory permissions are required, and whether the proposed buyer may lawfully possess them.

A contractual clause authorising the lender to sell collateral cannot, by itself, override statutory prohibitions.

B. Transfer of Property Act, 1882

The Transfer of Property Act governs mortgages and other transfers of property within its scope.

Its relevance depends on the asset being offered as security.

For example, a biotechnology company may mortgage its laboratory building while separately offering patents, equipment, or other movable assets as security.

A mortgage over real property does not automatically confer rights over every biological sample stored in the building.

The lender must distinguish between:

1. Ownership of the laboratory premises.
2. Ownership of equipment.
3. Rights in biological inventory.
4. Intellectual property associated with biological research.
5. Contractual rights relating to the use of biological materials.

Each category may require a different security arrangement.

C. Transplantation of Human Organs and Tissues Act, 1994

This statute is particularly important when a proposed lending arrangement involves human organs or tissues.

The Act regulates the removal, storage, and transplantation of human organs and tissues for therapeutic purposes and seeks to prevent commercial dealings in such materials. Section 19A specifically addresses illegal dealings in human tissues, while Section 19 addresses commercial dealings in human organs. India Code

The implications for secured lending are substantial.

A lender should not assume that a human organ or tissue can be treated like ordinary inventory merely because it has scientific or economic value.

If a proposed security arrangement depends on the commercial supply of human tissue in circumstances prohibited by the Act, the arrangement may create serious legal and criminal-law risks.

However, the Act should not be interpreted as automatically prohibiting every commercial activity involving every biological material. The precise material, purpose, transaction, and applicable statutory provisions matter.

For example, the legal treatment of human tissue intended for transplantation may differ from that of a lawfully manufactured pharmaceutical product or a patent covering a biotechnology process.

D. Biological research and biosafety regulations

Biological research materials may also be subject to applicable biosafety, biosecurity, laboratory, import-export, and environmental requirements.

For instance, the handling of genetically modified organisms may engage India's environmental and biotechnology regulatory framework.

A lender considering biological assets must therefore assess not only their commercial value but also whether possession, storage, transport, and transfer are legally permissible.

A default cannot eliminate these regulatory obligations.

E. Intellectual property legislation

Biotechnology-related intellectual property may provide a more practical basis for secured lending than biological specimens themselves.

Relevant legislation may include:

• The Patents Act, 1970.
• The Patents Act's applicable rules and provisions concerning ownership and assignment.
• The Plant Varieties Protection and Farmers' Rights Act, 2001.
• The Copyright Act, 1957, where qualifying works are involved.
• Contractual and confidentiality protections for trade secrets and know-how.

For example, a biotechnology enterprise might grant security over a patent covering a diagnostic technology rather than pledge human samples used during research.

The lender must still examine the validity of the patent, ownership, existing licences, transfer restrictions, and applicable registration or perfection requirements.

A patent is a legal right over an eligible invention; it does not confer unrestricted ownership of every biological specimen used to develop that invention.

4. Important Judicial Decisions and Their Relevance

There is no established body of Indian case law specifically recognising a general doctrine of biological collateral in lending. The following decisions address related principles that may guide the analysis.

The distinction is important: these cases are relevant by analogy; they should not be presented as judgments directly authorising the pledging of human biological materials.

Case 1: PTC India Financial Services Ltd. v. Venkateshwarlu Kari (2022)

Court: Supreme Court of India
Citation: Civil Appeal No. 5443 of 2019
Decision date: 12 May 2022

Official judgment: Supreme Court judgment

Facts and legal issue

The case concerned the enforcement of a pledge over securities and the relationship between the Indian Contract Act and the regulatory framework governing securities held in dematerialised form.

The Supreme Court considered whether the applicable securities-depository provisions displaced the established law governing pledges.

Judgment

The Court examined the legal nature of a pledge and the rights of the pawnor and pawnee. It explained the distinction between the limited security interest acquired by a pledgee and the broader ownership rights of the pledgor.

The decision also addressed the importance of the statutory requirements governing enforcement of pledged assets.

Relevance to biological collateral

The judgment provides a useful analytical framework for biological collateral.

A lender receiving a pledge does not necessarily become the absolute owner of the asset. Its rights are limited by the nature of the security and the applicable law.

Applied by analogy, a lender financing a biotechnology enterprise must distinguish between:

• Ownership of a biological specimen.
• Custody of the specimen.
• A contractual right to use the specimen.
• An intellectual property right associated with the specimen.
• A security interest over a legally transferable asset.

These are not interchangeable legal interests.

The judgment does not establish that human tissues or other biological materials are pledgeable. Their legal eligibility must be established independently.

Legal principle: The nature and extent of a lender's rights depend on the legally recognised security interest and the statutory framework governing the asset.

Case 2: Central Bank of India v. Siriguppa Sugars and Chemicals Ltd. (2007)

Court: Supreme Court of India
Decision date: 7 August 2007

The decision is identified among the authorities associated with Section 172 of the Indian Contract Act. IndiaCode by eCourtsIndia

Legal significance

The case is relevant to the legal framework governing pledged goods and the relationship between a bank's security rights and competing claims involving the pledged property.

It helps illustrate why the existence of a debt does not, by itself, answer every question about the lender's entitlement to an asset.

Application to biological collateral

Suppose a pharmaceutical company borrows money and provides eligible biological inventory as security.

A dispute might arise between the lender, the borrower, a supplier, or another party claiming rights in that inventory.

The court would need to examine the relevant security arrangement, the parties' legal interests, and the applicable statutory rules.

The same approach would be necessary if the purported collateral consisted of biological materials held under a research agreement or a third-party custody arrangement.

However, the case should not be interpreted as recognising a general right to seize or sell human biological material.

Legal principle: Security rights must be analysed in the context of the legally recognised interests in the particular asset.

Case 3: Parveen Begum v. Appellate Authority (2012)

Court: Delhi High Court
Citation: 189 (2012) DLT 427

Background

The dispute concerned the statutory framework governing human organ and tissue transplantation, particularly the distinction between permissible donations based on affection or attachment and prohibited commercial dealings.

The legal issue involved the operation of the transplantation framework where the donor and recipient were not near relatives.

Judgment's significance

The decision discussed the distinction between a permissible donation and a commercial transaction involving human organs or tissues.

The statutory framework does not prohibit every donation between unrelated persons. It regulates transplantation and prohibits specified commercial dealings.

The judgment is discussed in a later High Court decision concerning organ transplantation and the statutory authorisation process. Indian Kanoon

Application to biological collateral

This distinction is important when evaluating loans secured against human biological materials.

A lender cannot automatically infer from the fact that a biological material has value that it can be sold commercially.

The legal analysis must consider the nature of the material, the purpose of the proposed transfer, the statutory restrictions, and whether the arrangement involves a prohibited commercial transaction.

For example, a financing agreement that depends on selling human tissue in a manner prohibited by Section 19A cannot be made lawful merely by describing the transaction as the enforcement of collateral.

Legal principle: Commercial arrangements involving human biological materials must comply with the statutory restrictions applicable to those materials.

Limitation: This case concerns transplantation law, not secured lending. Its relevance is therefore indirect.

Case 4: Ajay Mittal v. Union of India (2022)

Court: High Court of Telangana
Decision date: 6 December 2022

The decision discusses the transplantation legislation and the distinction between prohibited commercial transactions and arrangements based on permissible considerations of affection or attachment. Indian Kanoon

Relevance

The case reinforces the need to assess the substance of an arrangement rather than relying solely on the terminology used by the parties.

In a biological-collateral dispute, a court would need to consider whether the transaction involves an independently transferable commercial asset or an attempt to commercialise a biological material in a manner prohibited by law.

A lender's contractual description of an asset as collateral would not settle that question.

Legal principle: The legality of a biological-material transaction depends on its substance and the governing statutory framework, not merely on the labels used in the agreement.

Limitation: This decision concerns transplantation-related issues rather than the enforcement of a security interest.

5. Can Human Biological Materials Be Used as Loan Collateral?

This is one of the most difficult questions in the subject.

The answer is not a universal yes or no. It depends on the type of material and the proposed transaction.

A. Human organs

Using a human organ as ordinary commercial collateral would raise extremely serious legal obstacles under the Transplantation of Human Organs and Tissues Act, 1994.

The prohibition on commercial dealings in human organs means that a lender cannot safely assume it may take possession of an organ and sell it following a borrower's default.

A private agreement cannot override applicable criminal law.

B. Human tissues and cells

Human tissues are expressly addressed by Section 19A.

Consequently, a proposed lending structure that depends on payment for the supply of human tissue must be examined carefully against the statutory prohibition.

A tissue bank or research institution may have lawful rights and obligations relating to collection, processing, storage, and distribution. Those rights do not automatically establish an unrestricted power to pledge or sell the tissue as collateral.

The relevant questions include:

1. Who lawfully controls the material?
2. What consent was obtained?
3. For what purpose may the material be used?
4. Is commercial supply permitted?
5. Would enforcement of the security require a prohibited transaction?

C. Embryos and reproductive materials

Embryos, sperm, and ova raise additional concerns involving reproductive autonomy, consent, privacy, and specialised statutory regulation.

They should not be treated as ordinary commercial inventory without examining the relevant legal framework.

A lender cannot assume that an agreement creating a security interest would authorise the transfer, use, or disposal of reproductive material.

D. Biological samples used for research

Research samples may be subject to consent forms, research protocols, institutional policies, confidentiality obligations, and restrictions on subsequent use.

The research institution's possession of a sample does not necessarily establish that it owns the sample outright or may sell it.

A security agreement must respect any legally binding restrictions on the sample's use or transfer.

E. Biological products

Lawfully manufactured biological products may be more suitable for secured lending where the borrower owns the products and may legally transfer them.

Examples may include eligible pharmaceutical inventory or agricultural biotechnology products.

Even here, a lender must assess storage requirements, product expiry, regulatory restrictions, and the availability of lawful purchasers.

Practical conclusion: In many biotechnology transactions, security over equipment, receivables, eligible intellectual property, or lawfully transferable inventory is more straightforward than security over human biological material itself.

6. Intellectual Property as Biological Collateral

A particularly important distinction exists between a biological material and the intellectual property associated with it.

Suppose a biotechnology company develops a patented process for producing a therapeutic protein.

The company might seek financing by granting security over its patent rights, subject to applicable law.

The lender would assess:

• Whether the patent is valid and in force.
• Whether the borrower owns the patent or has authority to grant security.
• Whether prior licences restrict enforcement or transfer.
• Whether the patent has commercial value.
• Whether applicable registration and perfection requirements have been satisfied.
• Whether the lender can transfer or realise the relevant rights following default.

The patent may be commercially valuable even though the biological specimens used during development cannot themselves be sold or pledged.

However, the lender must not confuse the right to exploit an invention with ownership of the biological materials associated with it.

Example

A company holds a patent covering a diagnostic technology and maintains human samples under a research protocol.

It borrows ₹5 crore from a bank.

The company proposes the following assets as security:

1. Its patent rights.
2. Laboratory equipment.
3. Eligible commercial inventory.
4. Human samples held for research.

The first three categories may provide potential security, subject to their individual legal requirements.

The fourth requires separate analysis. The company may lack authority to sell the samples, and the consent or research conditions may prohibit the proposed transfer.

The lender should therefore avoid assuming that every asset appearing on the company's balance sheet is legally available for enforcement.

7. Major Legal Issues in Biological Collateral Lending

A. Ownership versus possession

A laboratory may physically possess biological material without owning all the rights associated with it.

Possession, custody, ownership, and authority to transfer must be distinguished.

B. Consent and autonomy

Biological materials obtained from human donors may be subject to consent limitations.

A donor's consent to research does not automatically establish consent to commercial sale, use as security, or transfer to a lender.

C. Public policy and illegality

Under Section 23 of the Indian Contract Act, agreements whose object or consideration is unlawful may be void.

Where an arrangement depends on prohibited commercial dealings in human biological materials, the court must examine its legality rather than treating the security agreement as an ordinary commercial contract.

The consequences for the loan agreement, the security interest, and any related remedies depend on the circumstances and the applicable law.

D. Valuation difficulties

Biological materials can deteriorate, expire, become contaminated, or lose commercial value when research results change.

Their valuation may depend on:

• Storage conditions.
• Scientific reproducibility.
• Regulatory approval.
• Market demand.
• Remaining shelf life.
• Restrictions on transfer.
• The availability of qualified purchasers.

A lender must distinguish theoretical scientific value from the amount that could lawfully be realised following default.

E. Privacy and genetic information

Biological samples may contain identifiable or sensitive genetic information.

A lender taking control of a research company should not assume that it automatically acquires unrestricted rights to access or disclose the associated data.

Applicable privacy legislation, consent conditions, and confidentiality obligations may continue to apply.

F. Insolvency and competing claims

If a biotechnology borrower becomes insolvent, disputes may arise concerning ownership, custody, security interests, and the rights of third parties.

The resolution process cannot be treated as a mechanism for bypassing restrictions governing human biological materials.

The insolvency professional and secured creditors must identify the assets that legally belong to the debtor and determine which interests can lawfully be realised.

8. Comparative Perspective: United States Law

The United States provides important examples of how courts approach disputes concerning human biological materials, ownership claims, and the rights arising from research.

These cases do not directly establish rules for biological collateral in India, but they illustrate the distinction between physical specimens and associated commercial rights.

A. Moore v. Regents of the University of California (1990)

Court: Supreme Court of California
Citation: 51 Cal. 3d 120; 793 P.2d 479

Facts

John Moore underwent medical treatment, and his physician subsequently used cells obtained from his body in research that led to the development of a commercially valuable cell line.

Moore argued, among other things, that the researchers had improperly appropriated his biological materials.

Judgment

The court rejected his conversion claim concerning the cells under the circumstances presented, while recognising the importance of disclosure obligations arising from the physician-patient relationship.

The judgment distinguished the patient's interests in informed consent and disclosure from a claim of continuing ownership sufficient to support conversion.

Relevance to biological collateral

The case illustrates why the legal status of a biological specimen cannot be determined solely by its commercial value.

Even where biological material produces valuable research outcomes, the original source does not necessarily possess every proprietary right associated with the resulting invention or product.

Conversely, a research company cannot assume that all rights relating to a sample are unrestricted.

For lenders, the case highlights the need to identify precisely which legal rights the borrower actually holds.

Limitation: Moore is not a lending or secured-transactions case. It does not establish that biological samples may be pledged.

B. Greenberg v. Miami Children's Hospital Research Institute, Inc. (2003)

Court: United States Court of Appeals for the Eleventh Circuit
Citation: 264 F. Supp. 2d 1064 (S.D. Fla. 2003), affirmed in relevant part, 126 F. App'x 940 (11th Cir. 2005)

Background

The litigation involved families and organisations that contributed tissue samples and information for research concerning Canavan disease.

The dispute raised questions about the rights of contributors, the use of donated biological materials, and the commercial exploitation of research outcomes.

Relevance

The case demonstrates the legal importance of the conditions under which biological materials are donated and used in research.

For secured lending, the practical lesson is that a borrower's possession of biological samples does not automatically establish unrestricted commercial rights over those samples or every product derived from them.

The lender must examine the relevant agreements, consent conditions, intellectual property rights, and applicable law.

Limitation: The case concerns research-related claims rather than a lender's enforcement of biological collateral.

9. Duties of Lenders Accepting Biological Collateral

A prudent lender should conduct a specialised legal and commercial review before accepting any biological asset as security.

Step 1: Identify the asset

The lender should determine whether the proposed collateral is:

• Physical biological material.
• A manufactured biological product.
• A patent or other intellectual property right.
• A contractual licence.
• A receivable arising from lawful commercial activity.
• Equipment or other conventional property used in biotechnology.

Step 2: Verify the borrower's rights

The lender must establish whether the borrower owns the asset or merely possesses it under a licence, research agreement, custody arrangement, or other restricted relationship.

Step 3: Examine statutory restrictions

The lender should determine whether the asset is subject to restrictions on sale, transfer, possession, storage, export, or commercial exploitation.

Step 4: Review consent and contractual restrictions

Where human biological material is involved, the lender should review applicable consent conditions, research agreements, and relevant institutional obligations.

Step 5: Assess valuation and preservation

The lender should obtain appropriate scientific, technical, and financial advice regarding the asset's value and the conditions required to preserve it.

Step 6: Draft enforceable security documentation

The security agreement should identify the asset, the rights being charged, the permitted enforcement mechanisms, and the limitations arising from applicable law.

Step 7: Plan for default

The lender should determine whether it could legally take possession of, retain, transfer, or sell the asset.

If lawful enforcement is not possible, the lender should consider alternative collateral rather than relying on a potentially unenforceable security arrangement.

10. Hypothetical Case Study: Loan Secured Against Human Tissue

Consider the following hypothetical situation.

BioGen Research Pvt. Ltd. obtains a ₹10 crore loan from a financial institution.

The company offers the following as security:

1. Laboratory equipment valued at ₹2 crore.
2. Patent rights valued at ₹4 crore.
3. Commercial receivables valued at ₹2 crore.
4. Human tissue samples held for research, which the company values at ₹2 crore.

The company subsequently defaults.

Issue 1: Can the lender sell the laboratory equipment?

Potentially, yes, provided the borrower has the relevant ownership rights and the security has been validly created and can lawfully be enforced.

Issue 2: Can the lender enforce the patent security?

Potentially, yes, subject to the applicable intellectual property and security laws, the validity of the patent, and any relevant contractual or statutory restrictions.

Issue 3: Can the lender collect the receivables?

Potentially, yes, subject to the terms of the assignment or security arrangement, applicable law, and any relevant restrictions.

Issue 4: Can the lender sell the human tissue samples?

Not automatically.

The lender would need to establish that the proposed transaction is legally permissible and that the borrower has rights capable of being transferred.

If the proposed sale would constitute a prohibited commercial dealing in human tissue under Section 19A of the Transplantation of Human Organs and Tissues Act, 1994, the lender cannot rely on the security agreement to override that prohibition. India Code

Likely legal approach

The court would examine the nature of each asset separately.

The validity and enforceability of security over the equipment, patents, and receivables would not automatically determine the legal status of the human tissue samples.

The lender's rights would depend on the applicable law, the security documentation, and the legal interests held by the borrower.

Lesson: A loan may be secured by several different assets, but each asset must independently satisfy the legal requirements for the creation and enforcement of security.

11. Emerging Doctrine: Biological Collateral Governance

Although biological collateral is not an established, independent doctrine of Indian secured-transactions law, the subject can be analysed through a proposed governance framework.

This framework brings together existing principles of property law, contract law, privacy, bioethics, intellectual property, and financial regulation.

Principle 1: Legality before valuation

A biological asset should not be accepted as collateral merely because it has a high estimated monetary value.

The lender must first establish that the relevant rights can lawfully be created and enforced.

Principle 2: Consent-sensitive security

Where biological material originates from a human donor, the legal consequences of consent and restrictions on subsequent use must be examined.

Principle 3: Separation of material and information

Physical specimens, genetic information, research results, patents, and contractual rights should be treated as distinct assets unless the applicable law establishes otherwise.

Principle 4: Limited enforcement rights

A lender should acquire only those rights that the borrower can legally grant.

A security agreement should not be interpreted as creating broader ownership rights than the borrower possesses.

Principle 5: Scientific and financial accountability

The valuation process should account for scientific uncertainty, storage requirements, contamination risks, regulatory restrictions, and the possibility that the asset cannot be sold.

Principle 6: Protection against unlawful commercialisation

A lending structure must not be used to circumvent statutory restrictions on human organs, tissues, or other regulated biological materials.

These principles offer a useful analytical model for evaluating proposed biological collateral transactions. They should not be mistaken for a separate body of binding Indian law.

12. Summary of the Principal Legal Authorities

The Indian decisions above concern related legal questions; they do not collectively establish a binding doctrine authorising biological materials to be used as loan collateral.

13. Conclusion

Biological Collateral in Lending Law concerns the intersection of secured transactions, biotechnology, property rights, consent, public policy, and financial regulation.

The central challenge is not simply whether a biological material has monetary value. It is whether the borrower possesses a legally transferable interest and whether the lender can lawfully enforce its security following default.

In India, the Indian Contract Act, 1872, provides the general framework for pledges, while the Transplantation of Human Organs and Tissues Act, 1994, imposes important restrictions on commercial dealings in human organs and tissues. Intellectual property legislation and other regulatory frameworks may govern biotechnology-related assets separately.

The most important distinction is between using a lawfully transferable biotechnology asset as security and attempting to commercialise a biological material whose transfer or sale is legally restricted.

A patent, eligible commercial inventory, equipment, or receivable may provide a practical basis for financing a biotechnology enterprise. Human organs, tissues, embryos, and other sensitive biological materials require much more careful scrutiny and cannot automatically be treated as ordinary collateral.

Ultimately, biological collateral governance should rest on five foundations: lawful ownership, valid consent where applicable, enforceable security rights, scientific and commercial valuation, and compliance with statutory restrictions.

These principles help ensure that biotechnology financing can support legitimate innovation without undermining human autonomy, public health, or the rule of law.

Legal note: This is an academic overview, not a legal opinion on a particular lending transaction. The precise outcome depends on the biological material, the security instrument, the parties' rights, and the applicable law.